May 13 (Reuters) - Acerus Pharmaceuticals Corporation ASP.TO :
* ACERUS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS
* ACERUS PHARMACEUTICALS CORPORATION QTRLY TOTAL REVENUES $2.2 MILLION, UP 33%
* ACERUS PHARMACEUTICALS CORPORATION QTRLY LOSS PER SHARE $0.02
* ACERUS PHARMACEUTICALS CORPORATION - NON-CASH IMPAIRMENT CHARGE OF $2.5 MILLION ON VALUE OF ESTRACE INTANGIBLE ASSET IN QUARTER
* ACERUS PHARMACEUTICALS CORPORATION - CASH AS OF MARCH 31, WAS $5.0 MILLION VERSUS $3.8 MILLION ON DEC 31, 2018
* ACERUS PHARMACEUTICALS CORPORATION - DOES NOT APPEAR THAT COMPANY WILL RECEIVE A SHIPMENT OF ESTRACE UNTIL MID-2020